AbbVie Inc.
ABBVNew York Stock ExchangeFull coverage
Latest dossier
AI-generated
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers
Q3 of fiscal year 2026 · Published Nov 3, 2026,
AbbVie sells prescription medicines, mostly in the United States, and two immunology drugs, Skyrizi and Rinvoq, now bring in nearly half of its revenue and almost all of its growth. In the third quarter of 2026 revenue grew 10.3% to $17.404 billion and adjusted earnings again came in above the company's own range, but adjusted figures leave out the royalties AbbVie pays on Skyrizi and much of what it spends buying new drugs. The key question is what AbbVie earns after Skyrizi and Rinvoq lose exclusivity between 2031 and 2037, which depends on medicines it is still developing or buying. Moatsight estimates revenue of about $71.1 billion and GAAP diluted EPS of about $6.60 over the next four quarters.
What you pay
| Figure | At the close | 5-yr median | 5-yr range |
|---|---|---|---|
| P/E | No value: no close yet | No value: no price history | |
| EV/Sales | No value: no close yet | No value: no price history | |
| EV/EBITDA | No value: no close yet | No value: no price history | |
| Price/FCF | No value: no close yet | No value: no price history | |
| Market cap | No value: no close yet | ||
| Net debt and other claims(enterprise value minus market cap) | No value: no close yet | ||
| Enterprise value | No value: no close yet |
How the business is doing
| Figure | Last 12 months | 1-year change1-year | Yearly, 3 years | 8 quarters |
|---|---|---|---|---|
| Revenue | $66B | +10.7%(better for the company) | +6.2% | Each quarter is listed in the row's details. |
| Diluted EPS | $5.81 | +338.5%(better for the company) | +16.7% | Each quarter is listed in the row's details. |
| Free cash flow | $18.9B | −4.1%(worse for the company) | −8.6% | Each quarter is listed in the row's details. |
| Gross margin | 73.7% | +4.0 pp(better for the company) | +2.7 pp | Each quarter is listed in the row's details. |
| Operating margin | 32.2% | +17.0 pp(better for the company) | +1.6 pp | Each quarter is listed in the row's details. |
| Net margin | 15.7% | +11.7 pp(better for the company) | +1.3 pp | Each quarter is listed in the row's details. |
| Share count | 1.772B | 0.0% | 0.0% | Each quarter is listed in the row's details. |
How to read these figures
- Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
- 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
- Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
- 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
- n/m: not meaningful, such as a rate of change from a loss.
- Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.
Price
No closing prices are stored for this listing yet.
Facts
- Exchange
- New York Stock Exchange · USD
- Kind
- Common stock
- Security
- Common Stock